A trio of vascular experts including Raphaël Coscas (Paris, France), Alexandros Mallios (Paris, France) and Kate Steiner (Stevenage, UK) discuss the key findings of the IN.PACT™ AV Access trial–which was recently published in the New England Journal of Medicine (NEJM)–and what impact its data might have on patients and in clinical practice.
Mallios believes the data is “groundbreaking”, with all physicians agreeing that publication in the NEJM shows that it is a “high-quality” trial. The data itself highlighted a “significant” improvement in patency of the target lesion primary patency with the IN.PACT DCB compared to plain balloon angioplasty.
The experts further delve into what the findings mean for the quality of life of patients, and their own daily practices, with Coscas noting that the benefit of fewer reinterventions and hospitalisations is “huge”. Mallios adds that the data has shown improvement of the entire fistula, not just the primary patency, with the IN.PACT DCB which, for him, is “the most important and most relevant characteristic of this paper”. Concluding, Steiner notes that the IN.PACT AV Access data “adds weight” to the use of DCBs in her clinical practice.
This video is sponsored by Medtronic.
New England Journal Of Medicine publishes “outstanding” six-month IN.PACT AV Access™ results
‘Indisputable evidence’ that DCB is the “gold standard” for treating vascular access stenosis